Αρχική World News FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a... World News FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Από Ogkologos - 30 Οκτωβρίου, 2025 425 0 Facebook Twitter Google+ Pinterest WhatsApp Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Rare Melanoma Very Likely to Respond to Treatment with Pembrolizumab 5 Μαΐου, 2023 Professor Ian Tomlinson: “Philanthropy is priceless to science” 3 Ιουνίου, 2021 Antibody Drug Ejects Problematic Proteins from Cancer Cells 13 Δεκεμβρίου, 2023 EMA Recommends Granting a Conditional Marketing Authorisation for Tovorafenib 27 Μαρτίου, 2026 Φόρτωση περισσοτέρων HOT NEWS 27-Year-Old Fighting Stage IV Cancer Gets Hit By COVID-19 And Sepsis... Pembrolizumab May Help Prevent Early-Stage Melanoma from Returning Cancer in Lymph Nodes May Help Tumors Spread by Enlisting Immune... Banking on breakthroughs for children and young people